BioFire Diagnostics, Siemens Healthcare GmbH, F-Hoffman La Roche Ltd are Dominating the Europe Syndromic Multiplex Diagnostic Market in 2019

Europe Syndromic Multiplex Diagnostic Market is expected to grow with the CAGR of 7.0% in the forecast period of 2020 to 2027. The years considered for study are as mentioned below:

Access Full Reports@ https://www.databridgemarketresearch.com/reports/europe-syndromic-multiplex-diagnostic-market

Europe syndromic multiplex diagnostic market is a highly consolidated market, which includes specific number of key players. The market has witnessed increased strategic developments owing to favourable market scenario.   

The major players dealing in Europe syndromic multiplex diagnostic market are introducing strong range of products provider along with launching new services and adopting strategic initiative such as acquisition, agreement, business expansion, award and recognition into the market. This helped companies to maximize the sales with enhanced service portfolio.

  • In May 2020, BioFire Diagnostics (A Subsidiary of biomérieux SA) announced that they have received FDA Emergency use authorization for the BIOFIRE RP2.1 panel, which includes 22 pathogens that cause respiratory infections, including SARS-CoV-2 for COVID-19 disease. After this announcement, the company has enhanced their credibility in the market.

BioFire Diagnostics (A Subsidiary of biomérieux SA) is the dominating player in syndromic multiplex diagnostic market. The other key players existing in the market includes GenMark Diagnostics, Inc., QuantuMDx Group Ltd., Bio-Rad Laboratories, Inc., Thermo Fisher Scientific Inc., Siemens Healthcare GmbH, QIAGEN, Hologic, Inc., F. Hoffmann-La Roche Ltd, BD, Danaher, Curetis, Abbott, DiaSorin S.p.A., Bosch Healthcare Solutions GmbH (a subsidiary of Robert Bosch GmbH), Biocartis, Luminex Corporation, Seegene Inc. among others.

Europe Syndromic Multiplex Diagnostic MarketBioFire Diagnostics (A Subsidiary of biomérieux SA)

BioFire Diagnostics (A Subsidiary of biomérieux SA) is headquartered in U.S. The company is engaged in manufacturing and commercializing of advance systems for syndromic infectious disease diagnostics. The company offers broad portfolio of innovative products and services in Film Array and panels among which both are market focused category.  

For instance,

  • In June 2017, BioFire Diagnostics (A Subsidiary of biomérieux SA) has announced that they have received FDA 510 (K) clearance of their FilmArray Respiratory Panel 2 (RP2). FilmArray RP2 is used for 21 pathogens tests. After getting approval, the company has commercialized their product into the market and generated adequate revenue.

The company has a presence in the U.S.

Siemens Healthcare GmbH

Siemens Healthcare GmbH is headquartered in Erlangen, Germany was founded in the year 1896.

The company provides laboratory diagnostics, medical imaging, digital ecosystem, reading solutions among others worldwide. The company offers various product categories such as Medical Imaging, Laboratory Diagnostics, Point of Care Testing, Digital Health Solutions, Services & Consulting, Clinical Specialties, Accessories, OEM & Electronics & Healthcare IT among which Laboratory Diagnostics is focused category.

For instance,

  • In April 2020, Siemens Healthcare GmbH announced that they have launch molecular Fast Track Diagnostics (FTD) SARS-CoV-2 Assay test kit which is used in the diagnosis of SARS-CoV-2 virus, which causes the COVID-19. After this announcement, the company has enhanced their product portfolio and generates adequate revenue.

The company has a presence in Americas, Europe, Asia-Pacific, Middle East and Africa. In addition to it, the company also generates its revenue from the various subsidiary companies such as Fast Track Diagnostic Ltd. (Europe), Siemens Healthcare Medical Solutions Limited (Germany) and among others.

F- Hoffmann La Roche Ltd.

F- Hoffmann La Roche Ltd. AG is headquartered in Basel, Switzerland which was established in 1896. The company is engaged in the manufacturing and developing of diagnostic products in the areas such as oncology, and dermatology among others. The company has wide product categories such as pharmaceuticals, solutions for diagnostics & product for researchers among which solution for diagnostics are market focused category.

For instance,

  • In May 2020, F. Hoffmann-LA Roche Ltd announced that they have received the U.S. Food and Drug Administration (FDA) Emergency Use Authorization (EUA) for their product Cobas SARS-CoV-2 test, this product is used for the detection of SARSCoV-2, the virus which causes COVID-19 disease. Also the product has received CE mark approval in the Europe region. After receiving approval company has enhanced their product portfolio and has generated adequate revenue.

The company has a presence in Americas, Europe, Asia-Pacific, Middle East and Africa. In addition to it, the company also generates its revenue from the various subsidiary companies such as Roche Holding Ltd. (Switzerland), Chugai Pharmaceutical Co., Ltd. (Japan), Roche Algérie SPA (Algeria), mySugr GmbH (Austria) among others.